Targeting specific receptors to treat tumors in patients with neurofibromatosis type 1
TAM receptor inhibition in NF1-associated peripheral nerve sheath tumors
This study is looking at how a drug called cabozantinib can help stop tumor growth in people with neurofibromatosis type 1 (NF1) by targeting specific receptors, and if you have NF1, you might be able to join a trial to see if this treatment works for you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-10991777 on NIH RePORTER |
What this research studies
This research investigates the use of a drug called cabozantinib to inhibit certain receptors involved in the growth of tumors associated with neurofibromatosis type 1 (NF1). The study utilizes advanced animal models that mimic the development of these tumors to understand how they progress and respond to treatment. By focusing on specific kinases, particularly AXL, the research aims to find effective ways to prevent the transformation of benign tumors into malignant ones. Patients with NF1 may have the opportunity to participate in clinical trials that evaluate the effectiveness of this treatment approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with neurofibromatosis type 1, particularly those with plexiform neurofibromas or atypical neurofibromas.
Not a fit: Patients without a diagnosis of neurofibromatosis type 1 or those who do not have associated tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that significantly reduce the risk of tumor progression in NF1 patients.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in tumor treatment, suggesting potential for success in this approach.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Clapp, David W — Indiana University Indianapolis
- Study coordinator: Clapp, David W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.